Digitalis toxicity: Using immunotherapy when supportive care isn't enough: Postgraduate Medicine: Vol 91, No 6

Views

CrossRef citations to date

Altmetric

Preview

Digitalis is widely used, primarily for congestive heart failure and various cardiac arrhythmias. Because this agent has a narrow therapeutic index, mild toxicity is not uncommon. Severe toxicity, however, is unusual and is life-threatening. In this article, Dr Krisanda focuses on current diagnosis and management of serious digitalis toxicity, with emphasis on the proper use of digoxin immune Fab (antigen-binding fragments).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Digitalis toxicity

Using immunotherapy when supportive care isn't enough

Information for

Open access

Opportunities

Help and information

Digitalis toxicity

Using immunotherapy when supportive care isn't enough

Preview

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature